These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 18411004)
1. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy. Sega EI; Lu Y; Ringor M; Leamon CP; Low PS Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004 [TBL] [Abstract][Full Text] [Related]
2. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential. Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727 [TBL] [Abstract][Full Text] [Related]
3. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Lu Y; Sega E; Leamon CP; Low PS Adv Drug Deliv Rev; 2004 Apr; 56(8):1161-76. PubMed ID: 15094213 [TBL] [Abstract][Full Text] [Related]
4. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Lu Y; Sega E; Low PS Int J Cancer; 2005 Sep; 116(5):710-9. PubMed ID: 15828051 [TBL] [Abstract][Full Text] [Related]
5. Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies. Yi YS; Ayala-López W; Kularatne SA; Low PS Mol Pharm; 2009; 6(4):1228-36. PubMed ID: 19374407 [TBL] [Abstract][Full Text] [Related]
6. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567 [TBL] [Abstract][Full Text] [Related]
7. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Lu Y; Low PS Cancer Immunol Immunother; 2002 May; 51(3):153-62. PubMed ID: 11941454 [TBL] [Abstract][Full Text] [Related]
8. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500 [TBL] [Abstract][Full Text] [Related]
9. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697 [TBL] [Abstract][Full Text] [Related]
10. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164 [TBL] [Abstract][Full Text] [Related]
11. Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer. Bandara NA; Bates CD; Lu Y; Hoylman EK; Low PS Mol Cancer Ther; 2017 Mar; 16(3):461-468. PubMed ID: 27980109 [TBL] [Abstract][Full Text] [Related]
12. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Müller C; Schubiger PA; Schibli R Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798 [TBL] [Abstract][Full Text] [Related]
13. Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Sobotkova E; Duskova M; Tachezy R; Petrackova M; Vonka V Oncol Rep; 2009 Mar; 21(3):793-9. PubMed ID: 19212641 [TBL] [Abstract][Full Text] [Related]
14. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Shi W; Siemann DW Anticancer Res; 2006; 26(5A):3445-53. PubMed ID: 17094465 [TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma. Bruckheimer E; Harvie P; Orthel J; Dutzar B; Furstoss K; Mebel E; Anklesaria P; Paul R Cancer Gene Ther; 2004 Feb; 11(2):128-34. PubMed ID: 14671672 [TBL] [Abstract][Full Text] [Related]
16. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712 [TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058 [TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Lu Y; Xu LC; Parker N; Westrick E; Reddy JA; Vetzel M; Low PS; Leamon CP Mol Cancer Ther; 2006 Dec; 5(12):3258-67. PubMed ID: 17172429 [TBL] [Abstract][Full Text] [Related]
19. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065 [TBL] [Abstract][Full Text] [Related]
20. [Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet]. Tsujimoto H; Tsukioka S; Koizumi K; Nakagawa F; Uchida J; Sugimoto Y; Oka T; Fukushima M; Watanabe T Gan To Kagaku Ryoho; 2007 Mar; 34(3):413-8. PubMed ID: 17353633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]